Clene Inc (NASDAQ:CLNNW) — Market Cap & Net Worth
Market Cap & Net Worth: Clene Inc (CLNNW)
Clene Inc (NASDAQ:CLNNW) has a market capitalization of $16.76 ($16.76) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #32041 globally and #6445 in its home market, demonstrating a -66.04% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Clene Inc's stock price $0.00 by its total outstanding shares 9310 (9.31K). Also see CLNNW current and non-current assets for a full breakdown of the balance sheet.
Clene Inc Market Cap History: 2018 to 2025
Clene Inc's market capitalization history from 2018 to 2025. Data shows change from $1.86K to $16.76 (-46.97% CAGR). Also see CLNNW cash flow metrics for how efficiently the company converts equity into cash flow.
Clene Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Clene Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Clene Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Clene Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $9.31K | $206.00K | -$19.28 Million | 0.05x | N/A |
| 2021 | $4.02K | $723.00K | -$9.74 Million | 0.01x | N/A |
| 2022 | $232.75 | $473.00K | -$29.92 Million | 0.00x | N/A |
| 2023 | $392.88 | $654.00K | -$49.50 Million | 0.00x | N/A |
| 2024 | $465.50 | $342.00K | -$39.40 Million | 0.00x | N/A |
Competitor Companies of CLNNW by Market Capitalization
Companies near Clene Inc in the global market cap rankings as of September 18, 2026. Review CLNNW intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Clene Inc by market ranking:
- Prairie Lithium Limited (AU:PL9): Ranked #32032 globally with a market cap of $32.17 USD ( AU$45.47 AUD).
- Lion Financial Group Limited (NASDAQ:LGHLW): Ranked #32033 globally with a market cap of $29.69 USD.
- Neovacs S.A. (PA:ALNEV): Ranked #32042 globally with a market cap of $13.63 USD ( €11.66 EUR).
- Lexaria Bioscience Corp (NASDAQ:LEXXW): Ranked #32043 globally with a market cap of $11.49 USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #32032 | Prairie Lithium Limited | AU:PL9 | $32.17 | AU$0.01 |
| #32033 | Lion Financial Group Limited | NASDAQ:LGHLW | $29.69 | $0.00 |
| #32042 | Neovacs S.A. | PA:ALNEV | $13.63 | €0.25 |
| #32043 | Lexaria Bioscience Corp | NASDAQ:LEXXW | $11.49 | $0.00 |
Clene Inc Historical Marketcap From 2018 to 2025
Between 2018 and today, Clene Inc's market cap moved from $1.86K to $ 16.76, with a yearly change of -46.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $16.76 | -96.40% |
| 2024 | $465.50 | +18.48% |
| 2023 | $392.88 | +68.80% |
| 2022 | $232.75 | -94.21% |
| 2021 | $4.02K | -56.79% |
| 2020 | $9.31K | +1563.89% |
| 2019 | $559.53 | -69.95% |
| 2018 | $1.86K | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Clene Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.76 USD |
| MoneyControl | $16.76 USD |
| MarketWatch | $16.76 USD |
| marketcap.company | $16.76 USD |
| Reuters | $16.76 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Clene Inc
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis … Read more